Want to join the conversation?
Healthcare company $JNJ said Janssen Biotech has submitted a supplemental Biologics License Application (sBLA) for daratumumab to the US FDA. The application seeks to expand the current indication, using daratumumab in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!
$SGY is expected to achieve $6.17 price target in next year, with a minimum target of $3.00, due to the price increase of 27.85% to $6.29 during the last trading session.